CD122 – shared beta subunit of the IL-15 and IL-2 receptors, two targets for the figurative price of one – has drawn the eyes of many drug developers, among them Anaptysbio Inc., which will roll out phase Ib results in celiac disease during the fourth quarter of this year with ANB-033. The San Diego-based firm intends to weigh the candidate in a second inflammatory disease. A phase Ib study with ANB-033 in eosinophilic esophagitis will begin this quarter.
As the march toward a new therapy continues in metabolic dysfunction-associated steatohepatitis (MASH), new approaches are drawing Wall Street’s attention. Among them is Inventiva SA’s pan-PPAR approach.
BioWorld tracked 215 clinical trial readouts spanning phases I through III in December 2025, a sizeable increase from 170 updates in November, but below the 252 reported in October.
After reaching their peaks in late November, both the BioWorld Drug Developers Index and the Nasdaq Biotechnology Index finished the year slightly down from those highs.
Full-year biopharma deal value in 2025 reached $292.55 billion, the highest annual total in BioWorld’s records, following $78.93 billion in the fourth quarter (Q4). The annual total is a 27% increase from the $230.53 billion recorded in 2024.
After a “brutal” year, there is reason for optimism, with the fourth quarter seeing an upswing in deal numbers and the amount raised, according to the UK Bioindustry Association’s final tally of biotech financing in 2025.
RSS
